



مركز الكويت لمكافحة السرطان  
Kuwait Cancer Control Center

# IMAtinib (Gleevec® 400 mg)



\* I M A 4 0 0 - 0 0 - D L - C N - S A \*



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m<sup>2</sup>):

Indication(s):  Early GIST (Adjuvant).

First line treatment of Unresectable/Recurrent/Metastatic GIST.

Central line:  Available  NA

Allergies:  NKA  Yes, specify; \_\_\_\_\_

Parameters: Initiate treatment only if ANC  $\geq$  1000; HB  $\geq$  80; Plt  $\geq$  100,000

## Standard Protocol:

DRUG	DOSE	ADMINISTRATION
IMAtinib	400 mg PO once daily	To be given with a meal and a large glass of water.
To be given for 3 years.		

**Special instructions:** Avoid concomitant use of strong CYP3A4 inducers (eg, dexamethasone, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin); if concomitant use cannot be avoided, increase imatinib dose by at least 50% with careful monitoring.

## Treatment Description:

Cycle	Date	IMAtinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

## Important Notes:

Reported grade 3/4 toxicities:  None  Hematological  Non-Hematological

If yes; Did it indicate hospitalization?  Yes  No

Did it indicate chemo-delay for  $\geq$  7 days?  Yes  No

Did it indicate dose reduction?  Yes  No

Did it indicate G-CSF support?  Yes  No